Iain is a co-founder and CEO of Aldatu Biosciences. Also serving as Chief Science Officer, Iain is responsible for leading the advancement of Aldatu’s pathogen and drug resistance diagnostic technology in addition to guiding the company’s global health strategy.
Since founding Aldatu Biosciences in 2014, Iain have led the design, development, and validation of over 30 diagnostic tests using Pan Degenerate Amplification and Adaptation (PANDAA), the company’s core technology platform that he developed PANDAA at the Harvard School of Public Health to enable detection of drug resistant variants of HIV, one of the most challenging targets for molecular diagnostics. Aldatu’s HIV-1 drug resistance [HIVDR] genotyping assays are the first to use real-time PCR for the focussed genotyping of resistance mutations in patients failing treatment and have been purchased and independently validated by the National Health Laboratory Services in South Africa.
Iain undertook his post-doctoral training at the Harvard TH Chan School of Public Health, and the Botswana-Harvard AIDS Institute in Gaborone, Botswana, where he focused on HIV drug resistance. Iain maintained an academic appointment at the Harvard TH Chan School of Public Health until 2021.
Iain holds a Ph.D. in Pathology – specializing in molecular virology – from St John’s College, University of Cambridge (2008), and an LL.M. in International Law and B.Sc. in Virology from the University of Glasgow.